Brooks Laboratories
- Market cap
- ₹ 172 Cr.
- P/E
- 13.4x
- P/B
- 1.47x
- 52-week range
- 36.3 – 116
- ROE
- 22%
- ROCE
- 21%
- Dividend yield
- 0%
- Debt / equity
- 0.07
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Brooks Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)13.4 against a typical 34: cheaper than most peers (1st = cheapest).33rd of 220
- Sales growth−10% against a typical +15.6% from a year earlier.163rd of 197
- Profit growth−118.7% against a typical +18.9% from a year earlier.152nd of 160
- Share price, 3 months0% against a typical −0.5%.98th of 200
- Size₹ 171.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).123rd of 199
Latest announcements
Exchange filings and their impact on the company.
- Board approved demerger of manufacturing business with 97% of sales into WOS for separate listing on 1:1 basis.
Brooks Laboratories' board on October 14, 2026 approved demerger of its Baddi manufacturing business, which was Rs 82.87 crore or 96.66% of FY26 turnover, into its wholly-owned Abridge Speciality Limited. Shareholders will get 1 share of Abridge for every 1 share held, and Abridge will seek listing on BSE and NSE, with the two companies to be renamed Brooks Laboratories and Xuri Lifesciences respectively. The scheme needs stock exchange, SEBI, NCLT and shareholder approvals over an indicative 16-month timeline, creating two focused trading and manufacturing platforms with no cash consideration.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated BB by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE BB | Stable | 11 Nov 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 11 Nov 2025 | Reaffirmed | CARE BB | — | CARE | ₹ 12 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 13 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 29 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 6 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 14 Nov 2025 | Financial Results | To consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended 30 September 2025 and Other business |
| 13 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 and other business. |
| 28 May 2025 | Financial Results | To consider and approve the financial results for the period ended March 31, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 22 | 18 | 18 | 21 | 21 | 23 | 26 | 23 | 17 | 20 | 23 |
| Expenses | 25 | 25 | 27 | 20 | 24 | 22 | 25 | 22 | 21 | 16 | 20 | 24 |
| Operating Profit | −1 | −3 | −10 | −2 | −3 | −2 | −1 | 3 | 3 | 1 | 1 | −1 |
| OPM % | −4.5% | −15.5% | −53.8% | −10.7% | −16.4% | −7.3% | −5.4% | 12.3% | 10.8% | 4.4% | 3.4% | −5.8% |
| Other Income | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 7 | 6 | 5 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −2 | −4 | −10 | −2 | −4 | −2 | −1 | 10 | 8 | 6 | 2 | −2 |
| Tax % | 0% | 0.8% | 0% | 0% | 0% | 0% | 14% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −2 | −4 | −10 | −2 | −4 | −2 | −1 | 10 | 8 | 6 | 2 | −2 |
| EPS in Rs | −0.62 | −1.48 | −3.66 | −0.92 | −1.51 | −0.81 | −0.5 | 3.25 | 2.71 | 1.87 | 0.52 | −0.61 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 2%
- 3 Years
- 11%
- TTM
- −8%
- 10 Years
- —
- 5 Years
- 27%
- 3 Years
- 47%
- TTM
- 551%
- 10 Years
- −4%
- 5 Years
- −12%
- 3 Years
- −17%
- TTM
- —
- 10 Years
- —
- 5 Years
- −9%
- 3 Years
- −2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Prices are delayed and for information only. Nothing on this page is investment advice.